{
    "rcn": "207449",
    "acronym": "PROOF",
    "topics": "SC1-PM-09-2016",
    "title": "Penumbral Rescue by Normobaric O=O Administration in Patients With Ischaemic Stroke and Target Mismatch ProFile: A Phase II Proof-of-Concept Trial",
    "startDate": "01/01/2017",
    "endDate": "31/12/2021",
    "objective": "Ischemic stroke (IS), caused by occlusion of arteries that supply blood to the brain, remains a leading cause of mortality and morbidity in the world. Disruption of blood and oxygen supply to the brain leads to neuronal death in the ischemic core within minutes. The hypoperfused tissue surrounding the ischemic core, the penumbra, is at high risk for infarction over time but still salvageable. Neuroprotective ‚Äúbridging‚Äù, sustaining the penumbra until reperfusion, may widen the therapeutic window, make recanalization treatments accessible to more patients and improve overall IS outcomes.\nAs ischemic cell death is primarily mediated by hypoxia, increasing oxygen supply to the penumbra seems THE logical approach. In animal models of IS, normobaric hyperoxygenation (NBHO) significantly increased penumbral oxygen pressure and attenuated brain injury when initiated early after onset of ischaemia and vessel occlusion was transient (35 to 50% infarct volume reduction).\nThe PROOF project now seeks to demonstrate that NBHO (high-flow 100% oxygen at >45 L/min via a non-rebreather mask, or FiO2=1.0 for intubation/ventilation) reduces infarct growth from baseline to 24 hours compared to standard treatment if administered ‚â§3 hours after onset of anterior circulation IS, in patients with proximal vessel occlusion and salvageable tissue at risk. The study is multi-center, adaptive phase-IIb, randomized, open-label with blinded-endpoint (PROBE design).\nThe primary efficacy criterion will be infarct growth from baseline to 24 hours. Secondary endpoints will be NIHSS 24h, categorical shift in the pre-stroke modified Rankin Score, QoL and cognition at day 90.\nPotential surrogate biomarkers, health economics and societal impacts will be assessed.\nIf NBHO proves its neuroprotective potential in this selected population, phase-III trials in all IS patients may be undertaken. Considering its low costs and ease of use, NBHO may impact stroke care worldwide.",
    "totalCost": "5997347,49",
    "ecMaxContribution": "5778827,49",
    "coordinator": "EBERHARD KARLS UNIVERSITAET TUEBINGEN",
    "coordinatorCountry": "DE",
    "participants": "ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK;FAKULTNI NEMOCNICE U SV. ANNY V BRNE;HELSINGIN JA UUDENMAAN SAIRAANHOITOPIIRIN KUNTAYHTYMƒ;STROKE ALLIANCE FOR EUROPE;CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS;VASTRA GOTALANDS LANS LANDSTING;UNIVERSITAETSKLINIKUM HEIDELBERG;CENTRE HOSPITALIER SAINT ANNE DE PARIS;EPPDATA GMBH;KATHOLIEKE UNIVERSITEIT LEUVEN;FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA",
    "participantCountries": "FR;CZ;FI;BE;CH;SE;DE;ES",
    "projectParticipants": {
        "999541642": {
            "orgId": "999541642",
            "orgName": "FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA",
            "ecContrib": 679924
        },
        "999483830": {
            "orgId": "999483830",
            "orgName": "HELSINGIN JA UUDENMAAN SAIRAANHOITOPIIRIN KUNTAYHTYMÄ",
            "ecContrib": 137463
        },
        "999841081": {
            "orgId": "999841081",
            "orgName": "UNIVERSITAETSKLINIKUM HEIDELBERG",
            "ecContrib": 1350776
        },
        "999651640": {
            "orgId": "999651640",
            "orgName": "VASTRA GOTALANDS LANS LANDSTING",
            "ecContrib": 185600
        },
        "948646712": {
            "orgId": "948646712",
            "orgName": "ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK",
            "ecContrib": 434733
        },
        "994491822": {
            "orgId": "994491822",
            "orgName": "FAKULTNI NEMOCNICE U SV. ANNY V BRNE",
            "ecContrib": 118650
        },
        "999600909": {
            "orgId": "999600909",
            "orgName": "CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS",
            "ecContrib": 0
        },
        "933845288": {
            "orgId": "933845288",
            "orgName": "EPPDATA GMBH",
            "ecContrib": 737875
        },
        "923417206": {
            "orgId": "923417206",
            "orgName": "CENTRE HOSPITALIER SAINT ANNE DE PARIS",
            "ecContrib": 246814
        },
        "999991916": {
            "orgId": "999991916",
            "orgName": "EBERHARD KARLS UNIVERSITAET TUEBINGEN",
            "ecContrib": 1498743
        },
        "999991334": {
            "orgId": "999991334",
            "orgName": "KATHOLIEKE UNIVERSITEIT LEUVEN",
            "ecContrib": 321625
        },
        "999553573": {
            "orgId": "999553573",
            "orgName": "STROKE ALLIANCE FOR EUROPE",
            "ecContrib": 66625
        }
    },
    "calculatedTotalContribution": 5778828
}